~~<i id='A29BE254B8'><strike id='A29BE254B8'><tt id='A29BE254B8'><pre id='A29BE254B8'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：leisure time 2025-09-30 05:36:12 Page View：418

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Colonoscopy at 40? Study finds a possible benefit
Next article： ChatGPT in medicine: STAT answers readers' burning questions

comprehensive

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

A controversial new treatment promises to make little people taller

AhminHaider(center)andhisbrotherBelalHaider(right)workontheirhomeworkwiththeircousinZayyanAgboatwall

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Study links childhood stress with decline in older age

AdobeStressfulexperiencesduringchildhoodcouldhavemorefar-reachingeffectsthanpreviouslythought,contri

WSS

explore

explore

focus

comprehensive

Study links childhood stress with decline in older age